AuGC BioFund LP, together with AuGC Partners LLC and Evan Markegard, reports beneficial ownership of 84,000 shares of Palatin Technologies Inc. common stock, representing 4.7% of the class.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
AuGC BioFund LP, together with AuGC Partners LLC and Evan Markegard, reports beneficial ownership of 84,000 shares of Palatin Technologies Inc. common stock, representing 4.7% of the class. The group has shared voting and dispositive power over 84,000 shares and no sole voting or dispositive power. The percentage is based on 1,779,275 shares outstanding as of May 12, 2026, as reported by Palatin. AuGC Partners LLC and Mr. Markegard may be deemed beneficial owners through their advisory and control roles but expressly disclaim beneficial ownership under Rule 13d-4. The position is reported as ownership of 5 percent or less of the outstanding common stock.
Key Figures
Shares beneficially owned:84,000 sharesPercent of class owned:4.7%Shares outstanding:1,779,275 shares+3 more
6 metrics
Shares beneficially owned84,000 sharesCommon stock of Palatin Technologies Inc. reported by each of AuGC BioFund LP, AuGC Partners LLC, and Evan Markegard
Percent of class owned4.7%Ownership percentage of Palatin Technologies common stock for each reporting person
Shares outstanding1,779,275 sharesPalatin Technologies common stock outstanding as of May 12, 2026, used to calculate ownership percentage
Shared voting power84,000 sharesNumber of Palatin Technologies shares over which the reporting persons have shared power to vote or direct the vote
Sole voting power0 sharesNumber of Palatin Technologies shares over which the reporting persons have sole voting power
Shared dispositive power84,000 sharesNumber of Palatin Technologies shares over which the reporting persons have shared power to dispose or direct disposition
"may be deemed to be the beneficial owner of all shares of Common Stock"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared voting powerfinancial
"Shared Voting Power 84,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 84,000.00"
Exempt Reporting Adviserfinancial
"AuGC Partners LLC is an investment adviser that is registered as an Exempt Reporting Adviser"
Rule 13d-4regulatory
"Pursuant to Rule 13d-4 , as amended, AuGC Partners LLC and Mr. Markegard expressly disclaim"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Palatin Technologies (PTN) does AuGC BioFund report?
AuGC BioFund LP reports beneficial ownership of 84,000 shares of Palatin Technologies common stock, representing 4.7% of the outstanding class. This percentage is based on 1,779,275 shares outstanding as of May 12, 2026, as reported by Palatin.
Who are the reporting persons in this Palatin Technologies (PTN) Schedule 13G/A?
The reporting persons are AuGC BioFund LP, its investment adviser AuGC Partners LLC, and Evan Markegard. AuGC Partners advises the fund, and Markegard, as Managing Member of AuGC Partners, may be deemed to share investment and voting discretion over the reported shares.
What voting power does AuGC BioFund have over Palatin Technologies (PTN) shares?
AuGC BioFund LP, AuGC Partners LLC, and Evan Markegard each report 0 shares of sole voting power and 84,000 shares of shared voting power. They also report shared dispositive power over 84,000 shares and no sole dispositive power over any shares.
On what share count is AuGC’s 4.7% Palatin Technologies (PTN) ownership based?
The 4.7% ownership figure is based on 1,779,275 shares of Palatin Technologies common stock outstanding as of May 12, 2026. That outstanding share count was reported by Palatin in a Form 10-Q filed on May 13, 2026.
Do AuGC Partners LLC and Evan Markegard claim beneficial ownership of Palatin (PTN) shares?
AuGC Partners LLC and Evan Markegard may be deemed beneficial owners through advisory and control roles but expressly disclaim beneficial ownership of the securities under Rule 13d-4. They state the report should not be construed as an admission of beneficial ownership.
Is AuGC BioFund’s Palatin Technologies (PTN) position above 5% ownership?
No. The reporting group states ownership of 4.7% of the class, which is 5 percent or less of Palatin Technologies’ outstanding common stock. This status is specifically indicated in the ownership-of-5-percent-or-less section of the disclosure.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
PALATIN TECHNOLOGIES INC
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
696077601
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
696077601
1
Names of Reporting Persons
AuGC BioFund LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
84,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
84,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
84,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.7 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
696077601
1
Names of Reporting Persons
AuGC Partners LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
84,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
84,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
84,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.7 %
12
Type of Reporting Person (See Instructions)
IA, HC, OO
SCHEDULE 13G
CUSIP Number(s):
696077601
1
Names of Reporting Persons
Evan Markegard
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
84,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
84,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
84,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.7 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
PALATIN TECHNOLOGIES INC
(b)
Address of issuer's principal executive offices:
301 Carnegie Center Drive, Suite 304, Princeton, NEW JERSEY, 08540.
Item 2.
(a)
Name of person filing:
AuGC BioFund LP
AuGC Partners LLC
Evan Markegard
(b)
Address or principal business office or, if none, residence:
AuGC BioFund LP
c/o AuGC Partners LLC
10875 Kemah Lane
San Diego, CA 92131
AuGC Partners LLC
10875 Kemah Lane
San Diego, CA 92131
Evan Markegard
c/o AuGC Partners LLC
10875 Kemah Lane
San Diego, CA 92131
(c)
Citizenship:
AuGC BioFund LP - Delaware
AuGC Partners LLC - Delaware
Evan Markegard - United States
(d)
Title of class of securities:
Common Stock, par value $0.01 per share
(e)
CUSIP No.:
696077601
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
AuGC Partners LLC is an investment adviser that is registered as an Exempt Reporting Adviser with the Securities and Exchange Commission. AuGC Partners LLC, which serves as investment adviser to AuGC BioFund LP (the "Fund"), may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund. Mr. Markegard, as Managing Member of AuGC Partners LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund. Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, AuGC Partners LLC and Mr. Markegard expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that AuGC Partners LLC or Mr. Markegard are the beneficial owner of any of the securities reported herein.
AuGC BioFund LP - 84,000
AuGC Partners LLC - 84,000
Evan Markegard - 84,000
(b)
Percent of class:
Ownership percentage is based on 1,779,275 shares of common stock outstanding, par value $0.01 per share, as of May 12, 2026, as reported by the Issuer on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2026.
AuGC BioFund LP - 4.7%
AuGC Partners LLC - 4.7%
Evan Markegard - 4.7%
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Notes above.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
AuGC BioFund LP
Signature:
/s/ Evan Markegard
Name/Title:
Managing Member, AuGC Partners LLC, its General Partner
